Syros Pharmaceuticals Email Format

Pharmaceutical ManufacturingMassachusetts, United States11-50 Employees

Syros Pharmaceuticals is a small biotechnology company based in Cambridge, Massachusetts, focused on developing frontline therapies for hematologic malignancies. Its work centers on advancing treatment options for patients with blood cancers and related conditions. The company has programs that address beta-thalassemia and sickle cell disease, reflecting its emphasis on hematologic disorders.

In 2023, Syros disclosed clinical data from a Phase 1/1b study of SY-5609, a selective CDK7 inhibitor, illustrating activity in its early-stage pipeline across solid tumors such as pancreatic ductal adenocarcinoma and HR+ breast cancer. The firm positions itself within the pharmaceutical industry as a focused developer of hematology-focused therapeutics, targeting clinicians and patients seeking frontline treatment options. Based in Cambridge, it operates as a relatively small organization pursuing multiple development programs in hematology and related areas.

Sign up for free to view info

Company overview Employee directory